Who owns Dianthus Therapeutics, Inc. /DE/ (DNTH)? Elite investor 13F holders

2 tracked elite investors reported holding Dianthus Therapeutics, Inc. /DE/ as of 2026-09-30, including D.E. Shaw, Polen Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

2 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
D.E. ShawDIANTHUS THERAPEUTICS INCSHARE2026-09-302026-11-16 00:00:002475526.00 USD28115.000000SharesreduceOriginal filing
Polen Capital ManagementDIANTHUS THERAPEUTICS INCSHARE2026-09-302026-11-13 00:00:002194822.00 USD24927.000000SharesaddOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown